Translational research EXPLORE COVID-19 and the two Phase II clinical trials FORCE and ImmunONCOVID-20

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    N/A
  • Known Financial Commitments (USD)

    $7,956,000
  • Funder

    BPI-France
  • Principal Investigator

    Unspecified Unspecified Unspecified
  • Research Location

    France
  • Lead Research Institution

    INNATE PHARMA
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics
  • Research Subcategory

    Immunity
  • Special Interest Tags

    N/A
  • Study Type

    Clinical
  • Clinical Trial Details

    Clinical Trial, Phase II
  • Broad Policy Alignment

    Pending
  • Age Group

    Unspecified
  • Vulnerable Population

    Unspecified
  • Occupations of Interest

    Unspecified

Abstract

This funding will allow the Company to cover the development of its ongoing activities in COVID-19 which began in March 2020. Funded programs include the EXPLORE COVID-19 translational research study and the two FORCE Phase II clinical trials and ImmunONCOVID-20. Under this agreement with Bpifrance, the financing will be received in four successive installments. The first tranche of € 1.7 million was paid at signing, and the remaining three tranches will be paid based on the achievement of certain clinical milestones, notably related to the FORCE Phase II trial.